SIRT2 and neoplasm: Pharmacologic inhibition of SIRT2 enhanced antitumor immunity by promoting metabolic reprogramming toward a profound hyper-metabolic state with enhanced capacity for aerobic glycolysis in tumor-infiltrating T cells [133].